Daniel C. Edelman, Ph.D.
Daniel C. Edelman, Ph.D.
Facility Head
Head, Clinical Molecular Profiling Core

Center for Cancer Research
National Cancer Institute

Clinical Molecular Profiling Core
Bethesda, MD 20892-4605
301-435-2891

The CMPC Mission By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.

Areas of Expertise
genome, clinical

The CMPC Mission By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials. Core Activities: Research & Clinical (CLIA) The Clinical Molecular Profiling Core (CMPC) was established in 2006 under the auspices of the Center for Cancer Research, National Cancer Institute. The vision was to create a robust and scientifically advanced laboratory program that would bring the tools of genome technology to bear on NCI intramural clinical trials. It has become increasingly recognized in this new era of targeted therapies that critical aspects of tumor biology can be elucidated by analysis of the cancer genome. Clinical trial outcomes could be better characterized with analysis of cancer genomes with respect to properties such as copy number aberrations, epigenomics, mRNA, and micro-RNA profiles. Importantly, these data also can drive discovery of new tumor subsets and therapeutically relevant genomic features which can lead to personalized cancer treatments. The CMPC creates the opportunity to make the necessary molecular analyses available to any NCI clinical investigator. Being a CLIA compliant laboratory magnifies our impact which allows us to raise the bar on personalized cancer medicine. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.

Selected Publications
  1. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.
    Nat. Genet.. 46: 844-9, 2014. [ Journal Article ]
  2. Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, Davis S, Edelman DC, Merino MJ, He M, Zhang L, Meltzer PS, Kebebew E.
    J. Clin. Endocrinol. Metab.. 99: E329-37, 2014. [ Journal Article ]
  3. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
    Nat. Genet.. 46: 41861, 2014. [ Journal Article ]
  4. Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, Zhang L, Meltzer PG, Stratakis CA, Kebebew E.
    J. Clin. Endocrinol. Metab.. 99: E536-43, 2014. [ Journal Article ]
  5. Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S.
    J. Clin. Invest.. 124: 398-412, 2014. [ Journal Article ]
Name Position
Sven Bilke Ph.D. Staff Scientist
Allison Gomez Postbaccalaureate Fellow
J. Keith Killian M.D., Ph.D. Staff Clinician
David Petersen Research Biologist
Marbin Pineda Research Biologist
Holly S. Stevenson Ph.D. Research Biologist
Jennifer L. Walling M.S. Research Biologist
Yonghong Wang Ph.D. Research Biologist

Summary

The CMPC Mission By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.

Areas of Expertise
genome, clinical

Research

The CMPC Mission By developing and implementing state of the art genomic technologies, the Clinical Molecular Profiling Core maximizes the clinical benefits and biological insights derived from the analysis of biospecimens obtained from National Cancer Institutes clinical trials. Core Activities: Research & Clinical (CLIA) The Clinical Molecular Profiling Core (CMPC) was established in 2006 under the auspices of the Center for Cancer Research, National Cancer Institute. The vision was to create a robust and scientifically advanced laboratory program that would bring the tools of genome technology to bear on NCI intramural clinical trials. It has become increasingly recognized in this new era of targeted therapies that critical aspects of tumor biology can be elucidated by analysis of the cancer genome. Clinical trial outcomes could be better characterized with analysis of cancer genomes with respect to properties such as copy number aberrations, epigenomics, mRNA, and micro-RNA profiles. Importantly, these data also can drive discovery of new tumor subsets and therapeutically relevant genomic features which can lead to personalized cancer treatments. The CMPC creates the opportunity to make the necessary molecular analyses available to any NCI clinical investigator. Being a CLIA compliant laboratory magnifies our impact which allows us to raise the bar on personalized cancer medicine. In order to keep CMPC technologies at the state-of-the-art, the Core includes a technology research and development component in its mission to innovate and develop new cutting edge applications that would widen the applicability of genome technologies to clinically accessible samples.

Publications

Selected Publications
  1. Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, Gao J, Zucali PA, Calabrese F, Favaretto A, Rea F, Rodriguez-Canales J, Walker RL, Pineda M, Zhu YJ, Lau C, Killian KJ, Bilke S, Voeller D, Dakshanamurthy S, Wang Y, Giaccone G.
    Nat. Genet.. 46: 844-9, 2014. [ Journal Article ]
  2. Ellis RJ, Wang Y, Stevenson HS, Boufraqech M, Patel D, Nilubol N, Davis S, Edelman DC, Merino MJ, He M, Zhang L, Meltzer PS, Kebebew E.
    J. Clin. Endocrinol. Metab.. 99: E329-37, 2014. [ Journal Article ]
  3. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS.
    Nat. Genet.. 46: 41861, 2014. [ Journal Article ]
  4. Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, Zhang L, Meltzer PG, Stratakis CA, Kebebew E.
    J. Clin. Endocrinol. Metab.. 99: E536-43, 2014. [ Journal Article ]
  5. Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, Wallace TA, Issaq HJ, Zhou M, Killian JK, Stevenson HS, Karoly ED, Chan K, Samanta S, Prieto D, Hsu TY, Kurley SJ, Putluri V, Sonavane R, Edelman DC, Wulff J, Starks AM, Yang Y, Kittles RA, Yfantis HG, Lee DH, Ioffe OB, Schiff R, Stephens RM, Meltzer PS, Veenstra TD, Westbrook TF, Sreekumar A, Ambs S.
    J. Clin. Invest.. 124: 398-412, 2014. [ Journal Article ]

Team

Name Position
Sven Bilke Ph.D. Staff Scientist
Allison Gomez Postbaccalaureate Fellow
J. Keith Killian M.D., Ph.D. Staff Clinician
David Petersen Research Biologist
Marbin Pineda Research Biologist
Holly S. Stevenson Ph.D. Research Biologist
Jennifer L. Walling M.S. Research Biologist
Yonghong Wang Ph.D. Research Biologist